Tesaro Stock Could Have 41% Upside
November 15, 2017 at 14:09 PM EST
For months now, investors have worried that Tesaro (TSRO) has lost its edge as it faces increased competition for its ovarian cancer drug Zejula. Today, Leerink analyst Seamus Fernandez upgraded the drug maker to an Outperform with a $121 price target. Getty Images/iStockphoto In short, Fernandez sees the drug maker’s stock gaining more than 41% over […]
